JP2023539361A5 - - Google Patents
Info
- Publication number
- JP2023539361A5 JP2023539361A5 JP2023514397A JP2023514397A JP2023539361A5 JP 2023539361 A5 JP2023539361 A5 JP 2023539361A5 JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023514397 A JP2023514397 A JP 2023514397A JP 2023539361 A5 JP2023539361 A5 JP 2023539361A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- culture
- approximately
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073671P | 2020-09-02 | 2020-09-02 | |
| US63/073,671 | 2020-09-02 | ||
| PCT/US2021/071330 WO2022051749A1 (en) | 2020-09-02 | 2021-08-31 | Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539361A JP2023539361A (ja) | 2023-09-13 |
| JP2023539361A5 true JP2023539361A5 (cg-RX-API-DMAC7.html) | 2024-09-10 |
| JP7824934B2 JP7824934B2 (ja) | 2026-03-05 |
Family
ID=80492150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514397A Active JP7824934B2 (ja) | 2020-09-02 | 2021-08-31 | 操作されたナチュラルキラー細胞の増殖および細胞毒性の増強およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230265390A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4204560A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7824934B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230058167A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116568805A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021337000A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3191047A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300903A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022051749A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| CN113226340A (zh) | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| WO2024163619A1 (en) * | 2023-02-01 | 2024-08-08 | Nkarta, Inc. | Methods for expanding immune cells and related compositions and uses thereof |
| KR102669705B1 (ko) * | 2023-02-24 | 2024-06-10 | 이엔셀 주식회사 | 제대혈 유래 자연 살해 세포의 확장배양방법 |
| KR20240175366A (ko) * | 2023-06-12 | 2024-12-20 | 한국화학연구원 | Nk 세포의 증식 촉진 또는 활성화용 조성물 및 그의 용도 |
| WO2025220989A1 (ko) * | 2024-04-16 | 2025-10-23 | 주식회사 유씨아이테라퓨틱스 | 자연살해세포의 증폭 및 형질 도입 효율 증진용 피더 세포 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3487991B1 (en) * | 2016-07-25 | 2022-09-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing modified natural killer cells and methods of use |
| US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
| AU2018227583B2 (en) * | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| MX2019011570A (es) * | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| WO2019165121A1 (en) * | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| CN113226340A (zh) * | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| AU2020321354A1 (en) * | 2019-07-31 | 2022-03-03 | Nkarta, Inc. | Methods and compositions for enhanced expansion and cytotoxicity of natural killer cells |
-
2021
- 2021-08-31 IL IL300903A patent/IL300903A/en unknown
- 2021-08-31 CA CA3191047A patent/CA3191047A1/en active Pending
- 2021-08-31 JP JP2023514397A patent/JP7824934B2/ja active Active
- 2021-08-31 CN CN202180072917.0A patent/CN116568805A/zh active Pending
- 2021-08-31 KR KR1020237011188A patent/KR20230058167A/ko active Pending
- 2021-08-31 US US18/024,012 patent/US20230265390A1/en active Pending
- 2021-08-31 AU AU2021337000A patent/AU2021337000A1/en active Pending
- 2021-08-31 EP EP21865294.9A patent/EP4204560A4/en active Pending
- 2021-08-31 WO PCT/US2021/071330 patent/WO2022051749A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542399A5 (cg-RX-API-DMAC7.html) | ||
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| Tarazona et al. | Current progress in NK cell biology and NK cell-based cancer immunotherapy | |
| JP2022184852A5 (cg-RX-API-DMAC7.html) | ||
| Ljunggren et al. | Prospects for the use of NK cells in immunotherapy of human cancer | |
| Locatelli et al. | Natural killer cells in the treatment of high-risk acute leukaemia | |
| Lim et al. | GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo | |
| Pesce et al. | Human NK cell subsets redistribution in pathological conditions: a role for CCR7 receptor | |
| RU2019128544A (ru) | Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров | |
| Van Ostaijen-Ten Dam et al. | Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential | |
| JP2019523001A5 (cg-RX-API-DMAC7.html) | ||
| JP2017512484A5 (cg-RX-API-DMAC7.html) | ||
| JP2018500944A5 (cg-RX-API-DMAC7.html) | ||
| JP2016509839A5 (cg-RX-API-DMAC7.html) | ||
| JP2021522839A5 (cg-RX-API-DMAC7.html) | ||
| JP2012521215A5 (cg-RX-API-DMAC7.html) | ||
| JP5118624B2 (ja) | 新規なヒトt細胞集団 | |
| JP7572371B2 (ja) | 養子移入療法(Adoptive transfer therapies)におけるTリンパ球及びNK細胞の拡大増殖及び分化のための方法 | |
| Van Caeneghem et al. | Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities | |
| JP2024513522A5 (cg-RX-API-DMAC7.html) | ||
| Yang et al. | Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia | |
| CN115058393B (zh) | 一种包被刺激物、培养试剂盒和自然杀伤细胞的培养方法 | |
| Klingemann | Development and testing of NK cell lines | |
| Lu et al. | CD16+ CD56− NK cells in the peripheral blood of cord blood transplant recipients: a unique subset of NK cells possibly associated with graft‐versus‐leukemia effect | |
| WO2001075072A2 (en) | PRODUCTION OF TcR GAMMA DELTA T CELLS |